Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline.
Eighteen patients received tigecycline as treatment for infection due to multidrug-resistant gram-negative bacilli, including Acinetobacter baumannii and Klebsiella pneumoniae carbapenemase- and extended-spectrum beta-lactamase-producing Enterobacteriaceae. Pretherapy minimum inhibitory concentration values for tigecycline predicted clinical success. Observed evolution of resistance during therapy raises concern about routine use of tigecycline in treatment of such infections when other therapies are available.
Anthony
Kara B
KB
Division of Infectious Diseases, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104, USA. kara.anthony@uphs.upenn.edu
Fishman
Neil O
NO
Linkin
Darren R
DR
Gasink
Leanne B
LB
Edelstein
Paul H
PH
Lautenbach
Ebbing
E
D040981:Acinetobacter baumannii / Q000302:isolation & purification; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D024901:Drug Resistance, Multiple, Bacterial; D004755:Enterobacteriaceae / Q000302:isolation & purification; D005260:Female; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology*; D006801:Humans; D007711:Klebsiella pneumoniae / Q000302:isolation & purification; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D008911:Minocycline / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000078304:Tigecycline; D016896:Treatment Outcome; D001618:beta-Lactamases / Q000096:biosynthesis
D000900:Anti-Bacterial Agents; D000078304:Tigecycline; D001618:beta-Lactamases; D008911:Minocycline